<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388475</url>
  </required_header>
  <id_info>
    <org_study_id>OKN-007-IV-RMG-201</org_study_id>
    <nct_id>NCT04388475</nct_id>
  </id_info>
  <brief_title>Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma</brief_title>
  <official_title>A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oblato, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oblato, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II open-label study investigating the efficacy, safety and&#xD;
      pharmacokinetic(PK) properties of OKN-007 combined with temozolomide(TMZ) in patients with&#xD;
      recurrent glioblastoma(GBM). All patients will have been previously treated with the&#xD;
      standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and&#xD;
      in some cases treatment for recurrent disease. Patients with unequivocal recurrence (first or&#xD;
      greater) established by MRI and meeting inclusion and exclusion criteria, will be eligible&#xD;
      for OKN-007 treatment on this protocol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Anticipated">October 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide</measure>
    <time_frame>Through study completion up to 24 months</time_frame>
    <description>Evaluate incidents of Adverse Events during the subjects are taking OKN-007 with Temozolomide. Adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with decreased neurological function</measure>
    <time_frame>Change from baseline at Day 1 of each 28 day cycle</time_frame>
    <description>Neurologic function assessed by Neurologic Assessment in Neuro-Oncology (NANO) scale. The NANO Scale evaluates 9 major domains of neurologic function, with each domain being scored on a range from 0 (no deficits) to 2 or 3 (maximum deficits).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with decreased performance</measure>
    <time_frame>Change from baseline at Day 1 of each 28 day cycle</time_frame>
    <description>Number of participants with decreased performance assessed by Eastern Oncology Cooperative Group (ECOG) scale. Minimum 0 (normal function) and maximum 4 (maximum disability).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS) rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects who are alive after six months of starting treatment. OS is defined as the time from first treatment dose until date of death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic response rate</measure>
    <time_frame>24 months</time_frame>
    <description>To determine the objective response rate to study therapy using Radiographic Assessment in Neuro-Oncology (RANO) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) rate</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects who are alive and progression free after six months of starting treatment. PFS is defined as the time from first treatment dose until objective tumor progression on the RANO criteria or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of OKN-007 in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 10 time points during 24 hours after OKN-007 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of OKN-007 in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 10 time points during 24 hours after OKN-007 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of OKN-007 in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 10 time points during 24 hours after OKN-007 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Temozolomide in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 8 time points during 24 hours after Temozolomide administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Temozolomide in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 8 time points during 24 hours after Temozolomide administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Temozolomide in blood plasma</measure>
    <time_frame>Day 1 and Day 5 in Cycle 1 and 2 (28 Day Cycle)</time_frame>
    <description>The sample will be collected at 8 time points during 24 hours after Temozolomide administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Recurrent Malignant Glioma</condition>
  <condition>Brain Glioblastoma</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled in this study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OKN-007</intervention_name>
    <description>Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide (TMZ)</intervention_name>
    <description>Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed Glioblastoma based on histopathology or molecular profile analysis (WHO&#xD;
             Grade IV), following primary treatment with TMZ and radiotherapy (minimum of 50 Gy)&#xD;
             and at least two cycles of maintenance TMZ (5 days of a 28 day cycle) as first-line or&#xD;
             second-line treatment with another treatment regimen, excluding bevacizumab.&#xD;
&#xD;
          2. Patients must have medical records available documenting O6-methylguanine-DNA&#xD;
             methyltransferase (MGMT) promoter methylation status analysis or must have tumor&#xD;
             tissue samples available from prior GBM surgery or open biopsy for MGMT status&#xD;
             determination.&#xD;
&#xD;
          3. For patients with unresected recurrent tumor, unequivocal radiographic evidence of&#xD;
             tumor progression by MRI. These patients must have at least one measurable lesion.&#xD;
&#xD;
          4. Patients with recent resection of recurrent viable tumor are eligible following&#xD;
             post-operative MRI perfusion scan with or without measurable lesions.&#xD;
&#xD;
          5. No more than two prior lines of therapy for glioblastoma. Any second-line therapy is&#xD;
             acceptable, excluding bevacizumab as second line.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2&#xD;
&#xD;
          7. Full recovery (â‰¤ grade 1) from the toxic effects.&#xD;
&#xD;
          8. Adequate renal, liver and bone marrow function:&#xD;
&#xD;
               -  Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               -  Leukocytes &gt;3,000/mcL&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1,500/mcL&#xD;
&#xD;
               -  Platelets &gt;100,000/mcL&#xD;
&#xD;
               -  Total bilirubin â‰¤ 1.5 Ã— upper limit of normal (ULN)&#xD;
&#xD;
               -  AST (SGOT) / ALT (SGPT) â‰¤2.5 Ã— ULN&#xD;
&#xD;
               -  Creatinine clearance â‰¥ 60 mL/min&#xD;
&#xD;
        10. Patients must be â‰¥18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Early discontinuation of TMZ in prior line due to treatment related Adverse events&#xD;
             (AEs).&#xD;
&#xD;
          2. Second primary malignancy expected to require treatment within a 6 month period&#xD;
             (except adequately treated basal cell carcinoma of the skin).&#xD;
&#xD;
          3. Have received treatment within the last 28 days with a drug that has not received&#xD;
             regulatory approval for any indication at the time of study entry.&#xD;
&#xD;
          4. Serious concomitant systemic disorders&#xD;
&#xD;
          5. Patients with abnormal sodium, potassium, or creatinine levels â‰¥ grade 2.&#xD;
&#xD;
          6. Patients with prothrombin time/partial thromboplastin time (PT/PTT) or International&#xD;
             normalized ratio (INR) above the ULN.&#xD;
&#xD;
          7. Inability to comply with protocol or study procedures.&#xD;
&#xD;
          8. Patients who have received bevacizumab for recurrent glioblastoma or are planning to&#xD;
             initiate treatment with bevacizumab for tumor necrosis. (Past treatment with&#xD;
             bevacizumab for tumor necrosis is acceptable).&#xD;
&#xD;
          9. Patients receiving or planning to initiate treatment with the tumor treating fields&#xD;
             device (OptuneÂ®) (OptuneÂ® prior to enrollment is permitted).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shinwook Kang</last_name>
    <role>Study Director</role>
    <affiliation>Oblato, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alex E. KIM Project Manager</last_name>
    <phone>609-734-4329</phone>
    <email>Alex@oblatoinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru Pillay</last_name>
      <phone>205-934-1432</phone>
      <email>tpillay@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Louis Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Gilbert</last_name>
      <email>Kathryn.Gilbert@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Ekokobe Fonkem, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center - John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Archer</last_name>
      <phone>310-582-7460</phone>
      <email>Ashley.Archer@providence.org</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Naveed Wagle, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Stucky</last_name>
      <email>Judith.Stucky@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Michael Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosangela Spear</last_name>
      <phone>407-303-8203</phone>
      <email>rosangela.spear@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Herbert Newton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharif Makar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mintoff</last_name>
      <email>Smintof1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Tobias Walbert, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Carroll</last_name>
      <email>arcarrol@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Glenn Lesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smiddy</last_name>
      <email>stephanie.smiddy@utoledo.edu</email>
    </contact>
    <investigator>
      <last_name>Ronald Skeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Sun Kim-Suh</last_name>
      <email>HeeSun-Kim@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>James Battiste, MD.,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Temozolomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

